Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Rozanolixizumab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What is Rystiggo Rystiggo contains the active substance rozanolixizumab. Rozanolixizumab is a monoclonal antibody (a type of protein) designed to recognise and attach to FcRn, a protein that keeps the immunoglobulin G (IgG) antibodies in the body for longer. Rystiggo is used together with standard therapy in adults to treat generalised myasthenia gravis (gMG), an autoimmune disease that causes muscle weakness which can affect multiple muscle groups throughout the body. The condition can also lead to shortness of breath, extreme fatigue and difficulties swallowing. Rystiggo is used in adults with gMG that produces IgG autoantibodies against acetylcholine receptors or muscle-specific kinase. In generalised myasthenia gravis (gMG), these IgG autoantibodies (proteins of the immune system that attack parts of a person's own body) attack and damage proteins that are involved in communication between nerves and muscle, called acetylcholine receptors or muscle-specific kinase. By attaching to FcRn, Rystiggo reduces the level of IgG antibodies, including IgG autoantibodies, thereby helping to improve symptom of the disease. 2.
e Rystiggo
Do not use Rystiggo –
If you are allergic to rozanolixizumab or any of the other ingredients of this medicine (listed in section 6). 1
Warnings and precautions Talk to your doctor, pharmacist or nurse before using this medicine if any of the following applies to you: Myasthenic crisis Your doctor may not prescribe this medicine if you are, or are likely to be, on a ventilator due to gMG muscle weakness (myasthenic crisis). Inflammation of the membranes that surround the brain and spinal cord (aseptic meningitis) Aseptic meningitis has been observed in association with this medicine. Seek immediate medical attention if you develop symptoms of aseptic meningitis such as severe headache, fever, stiffness of the neck, nausea, vomiting and/or intolerance to bright light. Infections This medicine may reduce your natural resistance to infections. Before starting or during treatment with this medicine, inform your doctor if you have any symptoms of infection (feeling warm, fever, chills or shivering, cough, sore throat or fever blisters may be signs of an infection). Hypersensitivity (allergic reactions) This medicine contains a protein that can cause reactions such as rash, swelling or itching in some people. You will be monitored for signs of an infusion reaction during and for 15 minutes after treatment. Immunisations (vaccinations) Please inform your doctor if you have received a vaccine in the last 4 weeks, or if you plan to be vaccinated in the near future. Children and adolescents Do not give this medicine to children below the age of 18 years because the use of Rystiggo has not been studied in this age group. Other medicines and Rystiggo Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Taking Rystiggo with other medicines may decrease the effectiveness of those medicines, including therapeutic antibodies (such as rituximab) or subcutaneous or intravenous immunoglobulins. Other medicines, including subcutaneous or intravenous immunoglobulins, or interventions such as plasmapheresis (a process in which the liquid part of the blood, or plasma, is separated from blood that has been drawn from a person), may impair the effect of Rystiggo. Tell your doctor if you are taking or planning to take other medicines. Tell your doctor about your treatment with Rystiggo before you have a vaccination. This medicine may impair the effect of vaccines. Vaccination with so-called live-attenuated or live vaccines is not recommended during treatment with Rystiggo. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. The effects of this medicine in pregnancy are not known. You should not use this medicine if you are pregnant or think that you may be pregnant unless your doctor specifically recommends it. 2
It is not known whether this medicine passes into human milk. Your doctor will help you decide if you should breast-feed and use Rystiggo. Driving and using machines Rystiggo is not likely to affect your driving and use of machines. Rystiggo contains proline This medicine contains 29 mg of proline in each ml of medicine. Proline may be harmful for patients with hyperprolinaemia, a rare genetic disorder in which an excess of the amino acid, proline, builds up in the body. If you have hyperprolinaemia, tell your doctor and do not use this medicine unless your doctor has recommended it. Rystiggo contains polysorbate 80 This medicine contains 0.3 mg of polysorbate 80 in each ml of medicine. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies. 3.
How to use Rystiggo
Treatment with Rystiggo will be initiated and supervised by a specialist physician experienced in the management of neuromuscular or neuro-inflammatory disorders. How much Rystiggo is given and for how long You will be given Rystiggo in cycles of 1 infusion per week for 6 weeks. Your doctor will calculate the correct dose for you based on your weight: if you weigh at least 100 kg, the recommended dose is 840 mg per infusion (requiring 6 ml per administration) if you weigh from 70 kg to less than 100 kg, the recommended dose is 560 mg per infusion (requiring 4 ml per administration) if you weigh from 50 kg to less than 70 kg, the recommended dose is 420 mg per infusion (requiring 3 ml per administration) if you weigh from 35 kg to less than 50 kg, the recommended dose is 280 mg per infusion (requiring 2 ml per administration) The frequency of treatment cycles varies for each patient and your doctor will consider if and when a new treatment cycle is appropriate for you. Your doctor will advise you on how long you should be treated with this medicine.
Rystiggo will be given to you by a doctor or nurse. Rystiggo can also be injected by yourself. You and your doctor or nurse will decide if, after training by a healthcare professional, you can inject this medicine yourself. Another person may also give your injections after they have been trained. Do not give yourself or someone else Rystiggo until you have been trained on how to do it. If you or your caregiver inject Rystiggo, you or your caregiver must carefully read and follow the Instructions for administration at the end of this leaflet (see 'Instructions for use'). You will be given this medicine as an infusion under the skin (subcutaneous use). It is usually injected into the lower part of the tummy, below the belly button. Injections should not be given into areas where the skin is tender, bruised, red or hard. 3
The administration is done using an infusion pump set at a flow rate up to 20 ml/hr. The administration can also be done manually (by manual push, this means without an infusion pump) at a flow rate that is comfortable for you. If you receive more Rystiggo than you should If you suspect that you have been accidentally administered a higher dose of Rystiggo than prescribed, please contact your doctor for advice. If you forget or miss an appointment to receive Rystiggo If you miss a dose, please contact your doctor immediately for advice and to schedule another appointment to receive Rystiggo within the next 4 days. Thereafter, the next dose should be given according to the original dosing schedule until the treatment cycle is completed. If you stop using Rystiggo Do not stop using this medicine without talking to your doctor first. Interrupting or stopping treatment with Rystiggo may cause your symptoms of generalised myasthenia gravis to come back. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The below side effects, presented in order of decreasing frequency, have been observed with Rystiggo: Very common: may affect more than 1 in 10 people Headache (including migraine) Diarrhoea Fever (pyrexia) Common: may affect up to 1 in 10 people Rapid swelling under the skin in areas such as the face, throat, arms and legs (angioedema) Joint pain (arthralgia) Skin rash, sometimes with red bumps (rash papular) Injection site reaction including injection site rash, redness of the skin (erythema), inflammation, discomfort, and infusion site pain Nose and throat infections Nausea Vomiting Not known (frequency cannot be estimated from the available data)
effects not listed in this leaflet. You can also report side effects directly via: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
How to store Rystiggo
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the vial label and outer carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 °C – 8 °C). Do not freeze. Rystiggo may be removed from refrigerated storage, kept at room temperature (up to 25 °C) in the original outer carton package, for only one single period of up to 20 days. Do not use the medicine after this time period. There is a space on the box so you can write the date it was taken out of the refrigerator. Keep the vial in the outer carton in order to protect from light. Each vial of solution for injection must be used only once (single use). Any unused product or waste material should be disposed of in accordance with local requirements. Do not use this medicine if you notice that the liquid looks cloudy, contains foreign particles, or has changed colour. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
Rystiggo
30 – 120 minutes
! Keep this medicine out of the sight and reach of children. What is in the box
Step-by-step instructions 1. Get ready Step 1: Gather all the supplies you will need on a clean and flat work surface:
Rystiggo vial. Rystiggo Package Leaflet.
! Check your dose – you may need more than 1 vial to prepare your prescribed dose.
Syringe (5 -10 ml depending on your prescribed dose).
o
Transfer needle with 18G needle or larger diameter or a vented vial adaptor.
o
Infusion line with a 26G needle or larger diameter. The infusion line should be 61 cm in length or shorter.
o
Adhesive Bandage See-Through Dressing
Syringe
Sharps Container
Alcohol wipes.
o
Tape or see-through dressing.
o
Adhesive bandage.
o
Sharps container.
o
Bowl or paper towel to collect extra liquid when filling the infusion line.
o
Syringe pump – if you are using a pump.
Tape
Alcohol Wipe
Vial
Bowl
Infusion Line
Transfer Needle Vented Vial Adaptor
7
! The supplies above are for illustration only. Your specific supplies may look different.
Step 2: Clean your work surface and hands
2. Prepare the vial(s) and syringe ! Check your dose – you may need more than 1 vial to prepare your prescribed dose. Step 3: Remove the protective cap from the vial(s)
! If you are using a vented vial adaptor instead of a transfer needle, you can skip directly to Step 7. Syringe Plunger
Step 4: Attach the transfer needle to the syringe
Step 5: Draw air into the syringe
Syringe
Transfer Needle
Needle Cap
Step 6: Remove the needle cap from the transfer needle
Step 7: Insert the transfer needle or vented vial adaptor directly into the vial Follow the instructions for the transfer method you are using: Using transfer needle •
Place the vial on the table and insert the transfer needle straight through the rubber stopper.
Using vial adaptor •
Place the vial on the table and insert the vial adaptor straight through the rubber stopper.
•
Attach the syringe to the vented vial adaptor.
Step 8: Turn the vial and syringe
! If you are using a vented vial adaptor, you can skip directly to Step 11.
9
Step 9: Push air from the syringe into the vial
Needle is above medicine
Step 10: Get ready to fill the syringe
Step 11: Fill the syringe with as much medicine as possible ! Check your dose – you may need more than 1 vial to prepare your prescribed dose.
Adjust the needle tip to keep it in the liquid. This will help you to take as much medicine out of the vial(s) as possible.
10
Needle is in medicine
Step 12: Remove air from the syringe
Step 13: Remove the transfer needle from the vial and the syringe
Step 14: Re-check your dose
11
3. Prepare for infusion Step 15: Attach the infusion line onto the syringe
Step 16: Fill the infusion line with medicine
Do not use an area of skin which:
is tender, bruised, red or hard
has scars or stretch marks.
Clean the infusion area with an alcohol wipe and allow it to air-dry.
Step 18: Insert the infusion line needle
Step 19: Secure the infusion line needle
4. Infuse and finish Step 20: Start the infusion Follow the instructions for the infusion method you are using: Manual push o Sit back comfortably and push firmly on the syringe plunger to infuse the medicine. o
You should infuse the medicine at a speed that feels comfortable to you. Keep pushing until there is no more medicine left in the syringe.
o
Before and during the infusion, make sure that the infusion line does not twist or bend. If this happens, the flow of medicine can be interrupted. In this case, correct the bend in the infusion line and try again.
o
If it feels uncomfortable or if any of the medicine flows back into the infusion line, you can push more slowly.
Syringe pump
How to set up your syringe pump (set an infusion rate of up to 20 ml per hour).
o
How to set the occlusion alarm to maximum setting.
o
How to start the syringe pump.
o
What the various syringe pump sounds and alarms mean and how to manage them.
o
How to stop the syringe pump.
See-Through Dressing Tape
o
Place the syringe in the syringe holder and start the pump by following the pump instructions.
o
Sit back comfortably while the pump gives you the medicine.
o
Before and during the infusion, make sure that the infusion line does not twist or bend. If this happens, the flow of medicine can be interrupted. In this case, correct the bend in the infusion line and try again.
o
Once it has finished, stop the pump by following the pump instructions.
o
Take the syringe out of the syringe pump.
! Note: There will be some medicine left in the infusion line. This is normal and you can throw it away in the sharps container. Step 21: Finish the infusion and clean up
14
what Rystiggo contains –
–
The active substance is rozanolixizumab. Each ml of solution contains 140 mg of rozanolixizumab. Each vial of 2 ml contains 280 mg rozanolixizumab. Each vial of 3 ml contains 420 mg of rozanolixizumab. Each vial of 4 ml contains 560 mg rozanolixizumab. Each vial of 6 ml contains 840 mg rozanolixizumab. The other ingredients are: histidine, histidine hydrochloride monohydrate, proline, polysorbate 80, and water for injections. See section 2 Rystiggo contains proline and Rystiggo contains polysorbate 80.
What Rystiggo looks like and contents of the pack Rystiggo is a solution for injection. Each carton contains 1 vial of 2 ml, 3 ml, 4 ml or 6 ml solution for injection. Not all vials may be marketed. The solution is colourless to pale brownish-yellow, clear to slightly opalescent (pearly white). The devices used for administration should be procured separately. 5
Marketing Authorisation Holder UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom Manufacturer UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium This leaflet was last revised in August 2025.
————————————————————————————————————————-INSTRUCTIONS FOR USE Rystiggo (rozanolixizumab) Rystiggo 140 mg/ml solution, for subcutaneous use Single-Use Vial Read all of these instructions before using Rystiggo. A doctor or nurse will show you how to give yourself Rystiggo before you use it for the first time. Another person may also give your infusions after they have been trained. Do not give yourself or someone else Rystiggo until you have been shown how to do it. This information does not replace talking to your healthcare provider about your medical condition or treatment. If you are using an infusion pump (also known as a syringe pump) to give yourself Rystiggo, please read the instructions provided by your doctor or nurse on how to set up the pump. ! Important information you need to know before giving yourself or someone else Rystiggo
6
Protective Cap Rubber Stopper Aluminium Shield
Rystiggo 140 mg/ml solution for injection comes as injection containing 140mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Rystiggo 140 mg/ml solution for injection is rozanolixizumab.
This leaflet reproduces the patient information leaflet approved for Rystiggo 140 mg/ml solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Treatment should be initiated and supervised by specialist healthcare professionals experienced in the management of patients with neuromuscular or neuro- inflammatory disorders.
Posology
A treatment cycle consists of 1 dose per week for 6 weeks.
The following table indicates the recommended total weekly dose of rozanolixizumab according to the patient's body weight. One or more vials might be needed to meet the appropriate volume to be administered, depending on vial size availability.
Body weight
≥ 35 to < 50 kg
≥ 50 to < 70 kg
≥ 70 to < 100 kg
≥ 100 kg
Weekly dose (mg)
280 mg
420 mg
560 mg
840 mg
Weekly dose (ml)
2 ml*
3 ml*
4 ml*
6 ml*
* One ml of solution for injection contains 140 mg of rozanolixizumab. Each vial contains excess volume for priming of the infusion line, see “Instructions For Use” in the Package leaflet.
Subsequent treatment cycles should be administered according to clinical evaluation. The frequency of treatment cycles may vary by patient. In the clinical development program, most patients had treatment-free intervals of 4-13 weeks between cycles.
From cycle to cycle approximately 10% of patients had a treatment-free interval of less than 4 weeks.
If a scheduled infusion is missed, rozanolixizumab may be administered up to 4 days after the scheduled time point. Thereafter, the original dosing schedule should be resumed until the treatment cycle is completed.
Special populations
Elderly
No dose adjustment is required (see section 5.2).
Renal impairment
Limited safety and efficacy data is available in patients with mild to moderate renal impairment (eGFR > 45 ml/min/1.73 m2). No data is available in patients with severe renal impairment. No dose adjustment is considered necessary as the pharmacokinetics of rozanolixizumab are unlikely to be affected by renal impairment (see section 5.2).
Hepatic impairment
No data is available in patients with hepatic impairment. No dose adjustment is considered necessary as the pharmacokinetics of rozanolixizumab are unlikely to be affected by hepatic impairment (see section 5.2).
Paediatric population
The safety and efficacy of rozanolixizumab in children and adolescents below the age of 18 years have not been established. No data are available.
Method of administration
For subcutaneous use.
It is recommended that rozanolixizumab is administered subcutaneously preferably into the lower right or lower left part of the abdomen, below the belly button. Infusions should not be given into areas where the skin is tender, erythematous, or indurated.
During administration of the first treatment cycle and administration of the first dose of the second treatment cycle of rozanolixizumab, appropriate treatment for injection and hypersensitivity-related reactions should be readily available (see section 4.4).
For instructions on material specificities for administration, see below and section 6.6.
Before administering rozanolixizumab, the instructions for use must be read carefully, see section 6.6.
Rystiggo can be administered using:
• An infusion pump (also known as syringe pump), or
• By manual push with a syringe
Rystiggo can be self-administered or administered by a caregiver, following the Instructions for Use after proper training by a healthcare professional on how to administer subcutaneous infusions.
Infusion with a pump
Infusion pumps, syringes and infusion sets appropriate for subcutaneous administration of medicinal products should be used (see section 6.6). If not using a programmable pump, the volume in the syringe should be adjusted to the prescribed dose prior to administration. Rozanolixizumab administration using an infusion pump should be performed at a constant flow rate up to 20 ml/hr.
Infusion by manual push with a syringe
Syringes and infusion sets appropriate for subcutaneous administration of medicinal products should be used.
The volume in the syringe should be adjusted to the prescribed dose prior to administration.
Rozanolixizumab administration using a syringe should be performed at a flow rate that is comfortable for the patient. In clinical trials, infusion times by manual push ranged from 1 to 30 minutes with a median infusion time of 5 minutes per patient. This range of infusion times may serve as a guide when training the patient or caregiver.
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Myasthenic crisis
Treatment with rozanolixizumab in patients with impending or manifest myasthenic crisis has not been studied. The sequence of therapy initiation between established therapies for MG crisis and rozanolixizumab, and their potential interactions, should be considered (see section 4.5).
Aseptic meningitis
Aseptic meningitis (drug induced aseptic meningitis) has been reported following rozanolixizumab treatment. If symptoms consistent with aseptic meningitis (headache, pyrexia, neck stiffness, nausea, vomiting) occur, diagnostic workup and treatment should be initiated as per standard of care.
Infections
As rozanolixizumab causes transient reduction in IgG levels the risk of infections may increase (see section 5.1). Overall, in phase 3 studies in gMG, infections were reported in 45.2 % of all rozanolixizumab treated patients. No increase in the incidence of infections was observed from cycle to cycle. Serious infections were reported in 4.3 % of patients.
Treatment with rozanolixizumab should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. During treatment with rozanolixizumab, clinical signs and symptoms of infections should be monitored. If a clinically important active infection occurs, withholding rozanolixizumab until the infection has resolved should be considered.
Hypersensitivity
Infusion reactions such as rash or angioedema may occur (see section 4.8). In the clinical trial, these were mild to moderate. Patients should be monitored during treatment with rozanolixizumab and for 15 minutes after the administration is complete for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs during administration (see section 4.8), rozanolixizumab infusion should be discontinued and appropriate measures should be initiated if needed. Once resolved, administration may be resumed.
Vaccination
Immunisation with vaccines during rozanolixizumab therapy has not been studied. The safety of immunisation with live or live-attenuated vaccines and the response to immunisation with vaccines are unknown. All vaccines should be administered according to immunisation guidelines and at least 4 weeks before initiation of treatment. For patients that are on treatment, vaccination with live or live-attenuated vaccines is not recommended. For all other vaccines, they should take place at least 2 weeks after the last infusion of a treatment cycle and 4 weeks before initiating the next cycle.
Immunogenicity
In the pooled cyclic treatment data from the phase 3 program, after 1 treatment cycle of 6 rozanolixizumab weekly doses, 27.1 % (42/155) of patients developed antidrug antibodies and 10.3 % (16/155) had antibodies that were classified as neutralising.
Upon reinitiating therapy, the proportion of patients who developed antidrug antibodies and neutralising antibodies increased to 65 % (13/20) and 50 % (10/20) respectively, after 5 treatment cycles. Development of neutralising antibodies was associated with a 24 % decrease in overall plasma exposure of rozanolixizumab.
There was no apparent impact of immunogenicity on efficacy and safety (see sections 5.1 and 5.2).
Excipients
This medicinal product contains 29 mg of proline in each ml.
The use in patients suffering from hyperprolinaemia should be restricted to cases where no alternative treatment is available.
This medicinal product contains 0.3 mg of polysorbate 80 in each ml.
Polysorbates may cause allergic reactions.
No interaction studies have been performed.
As rozanolixizumab interferes with the FcRn recycling mechanism of immunoglobulin G (IgG), the serum concentrations of IgG-based medicinal products (e.g. monoclonal antibodies and intravenous immunoglobulin [IVIg]) and Fc–peptide fusion proteins are expected to be decreased if administered concomitantly or within 2 weeks after administration of rozanolixizumab. It is recommended to initiate these treatments 2 weeks after administration of rozanolixizumab and to monitor for attenuated efficacy of these medicinal products when administered concomitantly.
Treatment with IV or SC immunoglobulins, PLEX/plasmapheresis and immunoadsorption may reduce circulating levels of rozanolixizumab.
Vaccination during treatment with rozanolixizumab has not been studied and the response to any vaccine is unknown. Because rozanolixizumab causes a reduction in IgG levels, vaccination with live-attenuated or live vaccines is not recommended during treatment with rozanolixizumab (see sections 4.4 and 5.3).
Pregnancy
There are limited amount of data from the use of rozanolixizumab in pregnant women. In animal studies, offspring from treated dams had very low levels of IgG at birth, as expected by the pharmacological mode of action of rozanolixizumab (see section 5.3). However, animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development. Treatment of pregnant women with rozanolixizumab should only be considered if the clinical benefit outweighs the risks.
As rozanolixizumab is expected to reduce maternal antibody levels, and is also expected to inhibit the transfer of maternal antibodies to the foetus, reduction in passive protection to the newborn is anticipated. Therefore, risks and benefits of administering live / live attenuated vaccines to infants exposed to rozanolixizumab in utero should be considered (see section 4.4, subsection “Vaccination”).
Breast-feeding
It is unknown whether rozanolixizumab is excreted in human milk. Maternal IgG is known to be excreted in breast milk during the first days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to breast-fed infants cannot be excluded during this short period. Afterwards, use of rozanolixizumab could be considered during breast-feeding only if the clinical benefit outweighs the risks.
Fertility
The effect of rozanolixizumab on human fertility is not known. Animal studies do not indicate harmful effects with respect to fertility (see section 5.3).
Rozanolixizumab has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
The most commonly reported adverse reactions were headache (48.4 %), diarrhoea (25.0 %) and pyrexia (12.5 %).
Tabulated list of adverse reactions
Adverse reactions from clinical studies and post-marketing experience in gMG are listed in Table 1 below, classified by MedDRA System Organ Class (SOC). Within each SOC, the adverse reactions are ranked by frequency, with the most frequent reactions first.
Frequency categories are defined as follows: Very common ( ≥ 1/10); Common ( 1/100 to < 1/10); Uncommon ( ≥ 1/1 000 to < 1/100); Rare ( ≥ 1/10 000 to < 1/1 000); Very rare (< 1/10 000), not known (cannot be estimated from the available data).
Table 1: List of adverse reactions
MedDRA system organ class
Adverse reactions
Frequency category
Infections and infestations
Upper respiratory tract infections1
Common
Herpes viral infection*6
Not known
Nervous system disorders
Headache2
Very common
Aseptic meningitis*
Not known
Gastrointestinal disorders
Diarrhoea
Very common
Nausea*
Common
Vomiting*
Common
Skin and subcutaneous tissue disorders
Rash3
Common
Angioedema4
Common
Musculoskeletal and connective tissue disorders
Arthralgia
Common
General disorders and administration site conditions
Pyrexia
Very common
Injection site reactions5
Common
1 Includes cases of nasopharyngitis
2Includes headache and migraine
3 Includes rash, rash papular and rash erythematous
4 Includes swollen tongue
5 Includes injection site rash, reaction, erythema, inflammation, discomfort, and infusion site erythema, pain
6 Includes cases of Herpes Zoster, simplex and oral
*From spontaneous post-marketing reporting
Description of selected adverse reactions
Headache
In MG0003, headache was the most common reaction reported in 31 (48.4 %) and 13 (19.4 %) of the patients treated with rozanolixizumab and placebo, respectively.
Headache occurred most frequently after the first infusion of rozanolixizumab and within 1 to 4 days after infusion. Except for 1 (1.6 %) severe headache, all headaches were either mild (28.1 % [n=18]) or moderate (18.8 % [n=12]) and there was no increase in incidences of headache with repeated cyclic treatment.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There are no data on symptoms associated with an overdose. Single subcutaneous dose of up to 20 mg/kg (2 162 mg) and weekly subcutaneous doses of ≈ 10 mg/kg (1 120 mg) for up to 52 weeks have been administered per protocol in clinical studies without dose limiting toxicity. In case of overdose, it is recommended that patients are monitored closely for any adverse reactions, and appropriate supportive measures should be instituted immediately.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Rystiggo 140 mg/ml solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.